Loading...
In 2016, several industry-sponsored randomized trials suggested that the glucagon-like peptide-1 [GLP-1] analogues liraglutide (Victoza) and semaglutide (not FDA approved), and a sodium-glucose cotransporter-2 inhibitor, empagliflozin (Jardiance), when added to standard care, lower cardiovascular (CV) risk in patients with type 2 diabetes. The primary outcome of these trials was a composite of first occurrence of nonfatal myocardial infarction (MI), nonfatal stroke, or CV-related death.
In LEADER, researchers randomized 9340 patients with type 2 diabetes and high CV risk to once-daily subcutaneous liraglutide or placebo. After a median 3.8 years, significantly fewer patients in the liraglutide group than in the placebo group experienced the …